MetaCap

Abivax SA (ABVX) vs Grifols S.A. (GRFS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Grifols S.A. (GRFS) has outperformed Abivax SA (ABVX) over the past year, losing 3.0% versus a loss of 38.5%. Abivax SA is the larger company by market cap ($6.41 billion vs $5.55 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABVX-38.55%GRFS-2.98%
+25%-9%-42%
Nov 21, 20251 yearNov 20, 2026
ABVX+781.93%GRFS+0.74%
+1727%+803%-120%
Oct 16, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABVX versus GRFS key metrics
MetricABVXGRFS
Share price$73.20$8.15
Market cap$6.41B$5.55B
1-day change-9.24%-0.61%
YTD return-45.72%-12.83%
1-year return-38.55%-2.98%
5-year return—-25.30%
P/E ratio (TTM)—9.82
Forward P/E—6.55
EPS (TTM)$-6.08$0.83
Dividend yield0.00%1.30%
Annual dividend$0.00$0.00
52-week high$148.83$9.77
52-week low$62.70$6.96
Distance from 52-week high-50.82%-16.58%
Analyst consensusnonebuy
Avg. price target upside+123.47%+27.24%
Average volume1.35M628.64K
Shares outstanding87.54M258.22M
Employees9825,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GRFS has outperformed ABVX by 35.6 percentage points over the past year.
  • Grifols S.A. offers a meaningfully higher dividend yield (1.30% vs 0.00%).

About Abivax SA

ABVX stock →

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees

About Grifols S.A.

GRFS stock →

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.

Health Care · Biotechnology: Pharmaceutical Preparations · 25,000 employees

ABVX vs GRFS FAQ

Which is bigger, Abivax SA or Grifols S.A.?

Abivax SA (ABVX) is larger, with a market capitalization of $6.41B compared with $5.55B for Grifols S.A. (GRFS).

Which stock has performed better over the past year, ABVX or GRFS?

GRFS returned -2.98% over the past 12 months, compared with -38.55% for ABVX (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Abivax SA or Grifols S.A.?

Grifols S.A. pays a dividend yielding 1.30%, while Abivax SA does not currently pay a regular dividend.

Are Abivax SA and Grifols S.A. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons